Boston’s booming Seaport just reeled in another massive pharma partnership. Local biotech Ascidian Therapeutics said Wednesday it has struck a global research and licensing collaboration with Eli Lilly that could be worth up to $1.9 billion, tying the startup’s RNA exon-editing platform to Lilly’s genetic-medicine firepower for inherited kidney diseases.
Deal Details
Under the agreement, Ascidian is eligible to receive up to $1.9 billion through an undisclosed upfront payment, development and commercial milestone payments, and tiered royalties. The company is keeping the size of the upfront check under wraps for now. Ascidian will lead discovery and selected preclinical activities, while Lilly will take on additional preclinical work, clinical development, manufacturing, and commercialization, according to a press release from Ascidian Therapeutics.
Seaport Consolidation Helped Spark the Match
Ascidian executives say the relationship did not materialize out of thin air. The deal grew out of increasing contact between local biotechs and Lilly's Boston teams as the pharma giant built up a genetic-medicine hub on the waterfront. Ascidian's chief financial officer told the Boston Business Journal that Lilly's move to consolidate its genetic-medicines expertise at its Seaport building was “catalytic” for the partnership. Lilly opened its Lilly Seaport Innovation Center in 2024, according to The Boston Globe, a shift that local observers say has made the waterfront a much easier place for scrappy startups and big pharma to find each other.
How the Science Stacks Up
Ascidian's RNA exon editors are designed to excise and replace disease-causing exons at the RNA level, an approach intended to restore full-length, functional proteins without altering genomic DNA. The platform could reach large or highly variable kidney genes that other genetic approaches struggle to address. Industry coverage notes that Ascidian has already landed a heavyweight pharma partner in a 2024 deal with Roche that included a roughly $42 million upfront payment and up to $1.8 billion in milestones, which underscores why big drugmakers are chasing the platform, according to Fierce Biotech.
What to Watch Next
All eyes now turn to the lab and, eventually, the clinic. Investors and researchers will be tracking preclinical readouts, investigational new drug filings, and any move to human studies. Ascidian retains the right to pursue other kidney targets independently, per the company’s release from Ascidian Therapeutics. With Lilly continuing to add R&D capacity and sign large collaborations in Boston, local biotech watchers say this latest tie-up highlights how the city’s ecosystem is feeding partnerships that could push a new wave of genetic-medicine programs into the clinic.
